NIH-funded research NIH-funded research

Understanding cognitive variability in adults with Down syndrome and its link to Alzheimer’s disease biomarkers

Official title: Intraindividual cognitive variability in aging adults with Down syndrome: associations with Alzheimer's disease plasma biomarkers, neuropathology and clinical dementia

Funded at Rutgers Biomedical and Health Sciences · NIH-11413879 · Data updated 2026-11-12

A study of adults with Down syndrome to see if everyday ups and downs in thinking tests can predict Alzheimer’s-related changes and dementia using blood and brain biomarkers.

More s Disease research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionRutgers Biomedical and Health Sciences
NIH-funded
Lab location1 site (Newark, UNITED STATES)
Project startAugust 15, 2023
Project endMay 31, 2028
Funding year2026
Award (this year)$246,694
NIH project number5R00AG082864-04
Project IDNIH-11413879 on NIH RePORTER

Who could benefit from this research

Could help

Adults with Down syndrome who are part of or eligible for the ABC-DS dataset, with available cognitive testing and biomarker data.

Less likely to help

Individuals without Down syndrome or without access to the ABC-DS data may not directly benefit from this study.

What this research studies

People with Down syndrome have a higher risk of developing Alzheimer’s disease, and this project looks at a new, inexpensive way to flag early dementia by measuring fluctuations in cognitive test results. The researchers will use existing data from the ABC-DS study, analyzing memory, thinking speed, problem solving, and visuospatial skills over two time points to calculate intraindividual cognitive variability. They will then explore how these variability scores relate to blood biomarkers like beta-amyloid and tau, as well as brain imaging markers and clinical dementia symptoms. The goal is to identify a simple predictor that could help enroll suitable individuals in future anti-Alzheimer’s therapies.

Why it matters

Potential benefit: If successful, this could provide a low-cost, non-invasive way to identify DS individuals at higher risk for dementia and guide timely treatment decisions.

How similar studies have gone: This approach is being explored in the general population, with some promise, but its applicability to Down syndrome is still being investigated.

Where this research is happening

  • Rutgers Biomedical and Health Sciences
    Newark, United States
    Active

Researchers

  • Principal investigator: Fonseca, Luciana — Rutgers Biomedical and Health Sciences
  • Study coordinator: Fonseca, Luciana

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.